These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 29884215)

  • 1. CREBBP/EP300 bromodomains are critical to sustain the GATA1/MYC regulatory axis in proliferation.
    Garcia-Carpizo V; Ruiz-Llorente S; Sarmentero J; Graña-Castro O; Pisano DG; Barrero MJ
    Epigenetics Chromatin; 2018 Jun; 11(1):30. PubMed ID: 29884215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CREBBP/EP300 Bromodomain Inhibition Affects the Proliferation of AR-Positive Breast Cancer Cell Lines.
    Garcia-Carpizo V; Ruiz-Llorente S; Sarmentero J; González-Corpas A; Barrero MJ
    Mol Cancer Res; 2019 Mar; 17(3):720-730. PubMed ID: 30606771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MYC-Mediated Ribosomal Gene Expression Sensitizes Enzalutamide-resistant Prostate Cancer Cells to EP300/CREBBP Inhibitors.
    Furlan T; Kirchmair A; Sampson N; Puhr M; Gruber M; Trajanoski Z; Santer FR; Parson W; Handle F; Culig Z
    Am J Pathol; 2021 Jun; 191(6):1094-1107. PubMed ID: 33705753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlling Intramolecular Interactions in the Design of Selective, High-Affinity Ligands for the CREBBP Bromodomain.
    Brand M; Clayton J; Moroglu M; Schiedel M; Picaud S; Bluck JP; Skwarska A; Bolland H; Chan AKN; Laurin CMC; Scorah AR; See L; Rooney TPC; Andrews KH; Fedorov O; Perell G; Kalra P; Vinh KB; Cortopassi WA; Heitel P; Christensen KE; Cooper RI; Paton RS; Pomerantz WCK; Biggin PC; Hammond EM; Filippakopoulos P; Conway SJ
    J Med Chem; 2021 Jul; 64(14):10102-10123. PubMed ID: 34255515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition.
    Ghosh S; Taylor A; Chin M; Huang HR; Conery AR; Mertz JA; Salmeron A; Dakle PJ; Mele D; Cote A; Jayaram H; Setser JW; Poy F; Hatzivassiliou G; DeAlmeida-Nagata D; Sandy P; Hatton C; Romero FA; Chiang E; Reimer T; Crawford T; Pardo E; Watson VG; Tsui V; Cochran AG; Zawadzke L; Harmange JC; Audia JE; Bryant BM; Cummings RT; Magnuson SR; Grogan JL; Bellon SF; Albrecht BK; Sims RJ; Lora JM
    J Biol Chem; 2016 Jun; 291(25):13014-27. PubMed ID: 27056325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression.
    Ogiwara H; Sasaki M; Mitachi T; Oike T; Higuchi S; Tominaga Y; Kohno T
    Cancer Discov; 2016 Apr; 6(4):430-45. PubMed ID: 26603525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer.
    Zou LJ; Xiang QP; Xue XQ; Zhang C; Li CC; Wang C; Li Q; Wang R; Wu S; Zhou YL; Zhang Y; Xu Y
    Acta Pharmacol Sin; 2019 Nov; 40(11):1436-1447. PubMed ID: 31097763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP.
    Qian M; Zhang H; Kham SK; Liu S; Jiang C; Zhao X; Lu Y; Goodings C; Lin TN; Zhang R; Moriyama T; Yin Z; Li Z; Quah TC; Ariffin H; Tan AM; Shen S; Bhojwani D; Hu S; Chen S; Zheng H; Pui CH; Yeoh AE; Yang JJ
    Genome Res; 2017 Feb; 27(2):185-195. PubMed ID: 27903646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis and therapeutic targeting of the EP300 and CREBBP acetyltransferases in anaplastic large cell lymphoma and Hodgkin lymphoma.
    Wei W; Song Z; Chiba M; Wu W; Jeong S; Zhang JP; Kadin ME; Nakagawa M; Yang Y
    Leukemia; 2023 Feb; 37(2):396-407. PubMed ID: 36456744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bromodomain inhibition of the coactivators CBP/EP300 facilitate cellular reprogramming.
    Ebrahimi A; Sevinç K; Gürhan Sevinç G; Cribbs AP; Philpott M; Uyulur F; Morova T; Dunford JE; Göklemez S; Arı Ş; Oppermann U; Önder TT
    Nat Chem Biol; 2019 May; 15(5):519-528. PubMed ID: 30962627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia.
    Xu C; Fu H; Gao L; Wang L; Wang W; Li J; Li Y; Dou L; Gao X; Luo X; Jing Y; Chim CS; Zheng X; Yu L
    Oncogene; 2014 Jan; 33(1):44-54. PubMed ID: 23208504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma.
    Meyer SN; Scuoppo C; Vlasevska S; Bal E; Holmes AB; Holloman M; Garcia-Ibanez L; Nataraj S; Duval R; Vantrimpont T; Basso K; Brooks N; Dalla-Favera R; Pasqualucci L
    Immunity; 2019 Sep; 51(3):535-547.e9. PubMed ID: 31519498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth.
    Hashwah H; Schmid CA; Kasser S; Bertram K; Stelling A; Manz MG; Müller A
    Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9701-9706. PubMed ID: 28831000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivating mutations of acetyltransferase genes in B-cell lymphoma.
    Pasqualucci L; Dominguez-Sola D; Chiarenza A; Fabbri G; Grunn A; Trifonov V; Kasper LH; Lerach S; Tang H; Ma J; Rossi D; Chadburn A; Murty VV; Mullighan CG; Gaidano G; Rabadan R; Brindle PK; Dalla-Favera R
    Nature; 2011 Mar; 471(7337):189-95. PubMed ID: 21390126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying collagen VI as a target of fibrotic diseases regulated by CREBBP/EP300.
    Williams LM; McCann FE; Cabrita MA; Layton T; Cribbs A; Knezevic B; Fang H; Knight J; Zhang M; Fischer R; Bonham S; Steenbeek LM; Yang N; Sood M; Bainbridge C; Warwick D; Harry L; Davidson D; Xie W; Sundstrӧm M; Feldmann M; Nanchahal J
    Proc Natl Acad Sci U S A; 2020 Aug; 117(34):20753-20763. PubMed ID: 32759223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ITR‑284 modulates cell differentiation in human chronic myelogenous leukemia K562 cells.
    Yang JS; Lee CY; Cho HC; Lu CC; Kuo SC; Wen YF; Tsai FJ; Lee MR; Tsai SC
    Oncol Rep; 2018 Jan; 39(1):383-391. PubMed ID: 29138846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CREBBP/EP300 acetyltransferase inhibition disrupts FOXA1-bound enhancers to inhibit the proliferation of ER+ breast cancer cells.
    Bommi-Reddy A; Park-Chouinard S; Mayhew DN; Terzo E; Hingway A; Steinbaugh MJ; Wilson JE; Sims RJ; Conery AR
    PLoS One; 2022; 17(3):e0262378. PubMed ID: 35353838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of genetic stability at the EP300 and CREBBP loci in a panel of cancer cell lines.
    Tillinghast GW; Partee J; Albert P; Kelley JM; Burtow KH; Kelly K
    Genes Chromosomes Cancer; 2003 Jun; 37(2):121-31. PubMed ID: 12696060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function.
    Kumar M; Molkentine D; Molkentine J; Bridges K; Xie T; Yang L; Hefner A; Gao M; Bahri R; Dhawan A; Frederick MJ; Seth S; Abdelhakiem M; Beadle BM; Johnson F; Wang J; Shen L; Heffernan T; Sheth A; Ferris RL; Myers JN; Pickering CR; Skinner HD
    Nat Commun; 2021 Nov; 12(1):6340. PubMed ID: 34732714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between E1A binding to cellular proteins, c-myc activation and S-phase induction.
    Baluchamy S; Sankar N; Navaraj A; Moran E; Thimmapaya B
    Oncogene; 2007 Feb; 26(5):781-7. PubMed ID: 16862175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.